Navigation Links
Molecular profiling reveals differences between primary and recurrent ovarian cancers
Date:2/10/2012

La Jolla, Calif., February 10, 2012 There is a need to analyze tumor specimens at the time of ovarian cancer recurrence, according to a new study published in Molecular Cancer Therapeutics. Researchers used a diagnostic technology called molecular profiling to examine the differences in the molecular characteristics of primary and recurrent ovarian tumors and found significant changes for some biomarkers. This is the first study that examined potential differences in a broad biomarker panel in patient-matched primary versus recurrent ovarian cancers and underscores the importance of analyzing the most current tumor tissue in order to make the most informed decisions about treatment for recurrence.

Ovarian cancer is the most deadly of gynecological cancers, and is the fifth leading cause of cancer-related death among women in the United States. Treatment for recurrent ovarian cancer often follows a trial and error approach in spite of molecular profiling technologies available to inform treatment selection. Profiling technologies may be utilized at the time of ovarian cancer recurrence, but the tumor specimens that are analyzed are most often those obtained at initial diagnosis. This profiling of the primary tumor does not take into account changes that occur in recurrent tumors, which may have enabled their survival after chemotherapy treatment.

Lead author Deb Zajchowski, Ph.D., Scientific Director of The Clearity Foundation says, "These results highlight additional challenges for the treatment of recurrent ovarian cancer. The study helps us appreciate the degree to which tumor characteristics that may be useful for making treatment decisions may change over the course of this disease."

Dr. Zajchowski, Clearity Scientific Advisor Beth Y. Karlan, M.D. of Cedar-Sinai's Women's Cancer Program and colleagues analyzed data already collected by The Clearity Foundation and the Diane Barton Database. They employed 18 different immunohistochemical analyses at Clinical Laboratory Improvement Amendments (CLIA)-certified labs to analyze 43 matched tumor specimens from 19 advanced stage carcinoma patients for a panel of proteins that are correlated with drug response, discovering that expression levels of five different biomarkers were discordant in more than 40% of the matched tumor samples. These differences may be sufficiently large as to impact selection of therapy.

"These results demonstrate the dynamic genetic changes in ovarian cancers between diagnosis and recurrence. While the expression of these and other candidate response biomarkers should be evaluated in larger studies to better understand the clinical utility of profiling recurrent tumor specimens, this report highlights our urgent need to individualize our treatment approaches in order to improve ovarian cancer survival," says Dr. Karlan, Director of the Cedars-Sinai Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute and a renowned expert in the field of gynecologic oncology.

Ovarian cancers are very different from patient to patient, which means they are likely to respond differently to FDA-approved and investigational drugs. By identifying the alterations in each tumor's information pathways, molecular profiling enables the individualization of a patient's treatment by matching those tumor alterations with one or more drugs. The Clearity Foundation has developed a process for generating this personalized diagnostic information using commercially-available molecular profiling technologies and then analyzing the results using its Diane Barton Database.


'/>"/>

Contact: Pam Lord
pam@canalecomm.com
619-849-6003
The Clearity Foundation
Source:Eurekalert

Related medicine news :

1. ROCK off: Study establishes molecular link between genetic defect and heart malformation
2. Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
3. Mutated Kras spins a molecular loop that launches pancreatic cancer
4. Molecular fingerprint discovered that may improve outcomes for head and neck cancer patients
5. Toronto researchers obtain detailed molecular signature for Tankyrase
6. Unlocking the genetic and molecular mystery of soft-tissue sarcoma
7. A new molecular mechanism in breast cancer development
8. Molecular link between diabetes and cancer described
9. AACR-NCI-EORTC to hold molecular targets meeting in San Francisco
10. Nobel Laureate Bruce Beutler on molecular sensors as a trigger for autoimmune disease
11. Biodesign researchers to develop new reagent pipeline for molecular medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... In honor of National Physical Fitness and Sports Month in ... their fitness journey on social media. , The foot care company, which specializes ... product voucher each week during May to one winner. , “Whether the goal is ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... Huntington Beach, California announced today the release of Grow Healthy Vending’s newly revamped ... one of the fastest growing healthy vending providers in North America with locations ...
(Date:5/2/2016)... ... 2016 , ... Over $60 Billion is spent annually on products for our ... product review site for Toys, Tots, Pets & More (TTPM) announced the 15 winners ... at the Metropolitan Pavilion in New York City. , Chosen from a field of ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... MedPro Waste ... mail back service. MedPro now offers its mail back service for an all-inclusive ... we are now able to provide service to all of the clients in the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Further establishing itself as ... that the new WHIMZEES Variety Value Boxes were selected from over 1,000 entrants as ... Award. , WHIMZEES natural dental chews for dogs are a favorite product among ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, announced ... 2016 conference, presented by Joseph Gunnar & Co. ... New York . Nadav Kidron , CEO of ... Presentation Details:   PIONEERS 2016, presented ...
(Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
Breaking Medicine Technology: